A new low-calorie sweetener could also improve gut health

Artificial sweeteners have exploded in popularity because they let people consume sweets without the calories. However, while they're considered safe for human consumption, studies in animals and humans suggest that some of them can stimulate appetite, leading to increased food consumption and weight gain, as well as other negative health outcomes. So, researchers have been turning to the study of low-calorie or extremely sweet substances from natural sources as possible replacements. For example, galactooligosaccharides -- found in mammalian milk -- are low-calorie sugars with prebiotic activity that can be a source of energy for beneficial gut microbes, but they're not quite sweet enough to replace table sugar. Alternatively, extracts from the luo han guo fruit contain mogrosides -- compounds 200 to 300 times sweeter than table sugar. But these extracts sometimes have off-flavors, which can be removed with enzymes. So, F. Javier Moreno and colleagues wanted to take advantage of the best aspects of both natural substances, using enzymes to modify mogrosides while simultaneously producing galactooligosaccharides for a brand-new low-calorie sweetener.

The researchers started with lactose and mogroside V (the primary mogrosidein luo han guo fruit). When they added β-galactosidase enzymes, the researchers obtained a mixture that contained mostly galactooligosaccharides and a small amount of modified mogrosides. A trained sensory panel reported that the new combination had a sweetness similar to that of sucrose (table sugar), suggesting it could be acceptable to consumers. In test tube experiments, the new sweetener increased the levels of multiple human gut microbes that are beneficial, including Bifidobacterium and Lactobacillus bacterial species. In addition, increases in bacteria-produced metabolites, such as acetate, propionate and butyrate, indicated that the mixture could potentially have a prebiotic effect on the gut microbiome. The researchers say that the new sweetener holds promise in these initial analyses, and their next step is to more closely study the substance's impact on human gut health.

The authors acknowledge funding from Optibiotix Health Plc (York, U.K.), the Spanish Ministry of Science, Innovation and Universities, and the European Union's Horizon 2020 research and innovation program. One of the study's authors is employed by Optibiotix Health Plc.